← All stocks

Stock news timeline · DRREDDY

DR. REDDY S LABORATORIES

News timeline · Last 30 days

23 Aug 2026 – 21 Sep 2026 · Times in IST

Timeline updates
13
Bullish
4
Neutral
9
Bearish
0
Active days
8

News timeline

Showing 13 of 13 updates · Newest first

Friday, 18 Sep 20264 updates

AI sentiment: Bullish 53% confidence

Dr. Reddy’s Labs: Takeda and Co. Team Up to Market Qdenga, India’s First Approved Dengue Vaccine for Kids and Adults.

AI sentiment: Neutral 89% confidence

Dr. Reddy's Partners on Dengue Vaccine Qdenga, Launch by H1 2027

Dr. Reddy's partners with Takeda for exclusive distribution of Qdenga, India's first CDSCO-approved dengue vaccine, in private markets. Qdenga targets all four dengue serotypes; expected availability in H1 2027; collaboration enhances India's dengue prevention efforts. Source: BSE

AI sentiment: Bullish 85% confidence

Dr Reddy's Labs:Co. Agrees To Licensing Deal With Gilead For Once-Yearly Lenacapavir To Prevent HIV.

AI sentiment: Neutral 90% confidence

Dr Reddy's Gets License for Gilead's Lenacapavir, No SEBI Disclosure Needed

Dr Reddy’s confirms voluntary license for Gilead’s lenacapavir, as reported on Sep 17, 2026. Company states no material events requiring disclosure under SEBI Regulation 30. Source: BSE

Thursday, 17 Sep 20262 updates

AI sentiment: Neutral 66% confidence

Dr. Reddy's, Gilead Tie-Up for HIV Drug Lenacapavir

Dr. Reddy's signed royalty-free license with Gilead for lenacapavir HIV prevention. The agreement focuses on annual lenacapavir as an HIV prevention option. Source: Livesquawk

AI sentiment: Bullish 76% confidence

Dr Reddy's: Enters Royalty-Free License Agreement With Gilead For Annual Lenacapavir HIV Prevention.

Saturday, 12 Sep 20262 updates

AI sentiment: Neutral 83% confidence

Dr. Reddy’s Labs: USFDA Finishes Inspection At Dr. Reddy’s Labs Facility In Morelos, Mexico Receives Two Observations In Form FDA 2953

AI sentiment: Bullish 73% confidence

Dr Reddy's Mexico Unit Gets 2 USFDA Observations

Dr Reddy’s Mexico API facility receives two USFDA observations after records assessment. USFDA completed evaluation at Industrias Químicas Falcon de México, as per regulatory filing. Source: The Hindu BusinessLine

Thursday, 10 Sep 20261 update

AI sentiment: Neutral 94% confidence

Dr. Reddy's Allots 375 Shares via ESOPs

Dr. Reddy's allotted 375 equity shares under its ESOPs on Sept 10, 2026. Post-allotment, total issued share capital stands at Rs. 83.46 crore. Source: BSE

Wednesday, 02 Sep 20261 update

AI sentiment: Neutral 86% confidence

Drugmakers May Soon Need To Clearly Label Medicines As Synthetic Or Biological Under New Rules - Mint ( Biocon, Dr. Reddy, Zydus ) - Newspaper

Thursday, 27 Aug 20261 update

AI sentiment: Neutral 75% confidence

Dr. Reddy's Sees ₹76 Cr Block Deal on BSE at ₹1,174/Share

Dr. Reddy's traded ~647,500 shares via BSE block trade at Rs 1,174. Total transaction value reached ~Rs 76.02 crore in this trade. Source: Livesquawk

Wednesday, 26 Aug 20261 update

AI sentiment: Neutral 95% confidence

Dr Reddy's Allots 4,110 Shares Under ESOP, Total Capital at ₹83.46 Cr

Dr Reddy's allotted 4,110 equity shares under its ESOP scheme on August 26, 2026. Shares rank pari passu with existing shares; total issued share capital now Rs. 83.46 crore. Source: BSE

Monday, 24 Aug 20261 update

AI sentiment: Neutral 68% confidence

India Preps New Semaglutide Standards For Manufacturing & Testing As Rising Weight-loss Drug - Newspaper ( Dr Reddy’s, Biocon, Sun Pharma, Zydus Lifesciences & Lupin )